Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$1.44 USD
-0.06 (-4.00%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.42 -0.02 (-1.39%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APRE 1.44 -0.06(-4.00%)
Will APRE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
Other News for APRE
Is APRE building bullish momentum? Stochastic Buy Signal shows up after a flat session
Is APRE poised for a breakout? NR7 shows up after climbing 3.09%
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
New 52 Week Closing Low appears for APRE after 3.64% move
APRE forms 20 Day Moving Average Resistance on September 15